Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 408.00K | 989.00K | 2.13M | 2.20M | 2.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 408.00K | 989.00K | 2.13M | 2.20M | 2.85M |
| Cost of Revenue | 20.50M | 29.46M | 40.74M | 50.26M | 60.71M |
| Gross Profit | -20.09M | -28.47M | -38.60M | -48.06M | -57.86M |
| SG&A Expenses | 30.06M | 28.50M | 28.21M | 28.82M | 28.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.56M | 57.95M | 68.95M | 79.08M | 89.55M |
| Operating Income | -50.15M | -56.96M | -66.82M | -76.88M | -86.69M |
| Income Before Tax | -51.03M | -57.21M | -62.01M | -75.48M | -85.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.03 | -57.21 | -62.01 | -75.48 | -85.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.03M | -57.21M | -62.01M | -75.48M | -85.82M |
| EBIT | -50.15M | -56.96M | -66.82M | -76.88M | -86.69M |
| EBITDA | -49.38M | -56.11M | -66.05M | -72.76M | -78.87M |
| EPS Basic | -28.02 | -31.44 | -34.12 | -41.60 | -47.42 |
| Normalized Basic EPS | -15.81 | -17.94 | -21.33 | -24.76 | -28.40 |
| EPS Diluted | -28.02 | -31.44 | -34.12 | -41.60 | -47.42 |
| Normalized Diluted EPS | -15.81 | -17.94 | -21.33 | -24.76 | -28.40 |
| Average Basic Shares Outstanding | 7.28M | 7.28M | 7.27M | 7.26M | 7.24M |
| Average Diluted Shares Outstanding | 7.28M | 7.28M | 7.27M | 7.26M | 7.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
